- October 13, 2026NEW YORK, October 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies…
- October 7, 2026– Four Accepted Abstracts Further Characterize Investigational Vidofludimus Calcium’s Profile in Multiple Sclerosis Across Long-Term Disability Outcomes, EBV-Related Immune Activity…
- September 29, 2026NEW YORK, September 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for…
- September 2, 2026NEW YORK, September 2, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral…
- September 1, 2026– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA…
- August 11, 2026– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board…
- August 10, 2026– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE…
- July 9, 2026NEW YORK, July 9, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral…
- June 10, 2026NEW YORK, June 10, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies…
- May 28, 2026– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –…
